Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Hydroxychloroquine Clear all
Completed Phase 3 Interventional Results available

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, csDMARDs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 6, 2026, 2:55 PM EDT
Not listed Phase 4 Interventional

Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease

NCT04429867
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
WellStar Health System
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 6, 2026, 2:55 PM EDT
Recruiting Early Phase 1 Interventional

HCQ in Resectable Localized Prostate Cancer

NCT06408298
View directory record Official record
Conditions
Resectable Localized Prostate Cancer
Interventions
Hydroxychloroquine Sulfate 400Mg Tab, Placebo
Drug
Lead sponsor
Lionel.D.Lewis, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 1 Interventional

Hydroxychloroquine in Outpatient Adults With COVID-19

NCT04333654
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Hydroxychloroquine SAR321068, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 6, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer

NCT02124681
View directory record Official record
Conditions
Insulin Resistance
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 69 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 6, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00531817
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Permitted DMARDs
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
156
States / cities
Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

NCT01537315
View directory record Official record
Conditions
Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
Interventions
Hydroxychloroquine, Matching Placebo
Drug · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 6, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Pre-exposure Prophylaxis for SARS-Coronavirus-2

NCT04328467
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection

NCT04372017
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 1 Interventional Results available

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT04809623
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
Edecesertib, Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Beverly Hills, California • Clearwater, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 6, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT

NCT03283566
View directory record Official record
Conditions
Chronic Pancreatitis, Insulin Dependent Diabetes
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional Results available

A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

NCT04605588
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
Nitazoxanide, Placebo Nitazoxanide, Ribavirin, Placebo Ribavirin, Hydroxychloroquine, Placebo Hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

NCT04329923
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 6, 2026, 2:55 PM EDT
Suspended Phase 3 Interventional

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

NCT04363203
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
Hydroxychloroquine, Azithromycin, Placebo oral tablet
Drug
Lead sponsor
Salomeh Keyhani MD
Federal
Eligibility
216 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2020 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

NCT03428945
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional

Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

NCT04373044
View directory record Official record
Conditions
Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Baricitinib, Hydroxychloroquine, Placebo Administration
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 6, 2026, 2:55 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 6, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

NCT04308668
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus, Coronavirus Infections
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 6, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis

NCT00579878
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate-Sulfasalazine-Hydroxychloroquine, Leflunomide-Sulfasalazine-Hydroxychloroquine
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 6, 2026, 2:55 PM EDT
Withdrawn Phase 2 Interventional

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

NCT04379492
View directory record Official record
Conditions
COVID-19, COVID19, Sars-CoV2, SARS-Cov-2
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 6, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

University of Utah COVID-19 Hydrochloroquine Trial

NCT04342169
View directory record Official record
Conditions
Coronavirus Infection, Coronavirus, Infectious Disease
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 6, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional Results available

Treating COVID-19 With Hydroxychloroquine (TEACH)

NCT04369742
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine (HCQ), Placebo: Calcium citrate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 6, 2026, 2:55 PM EDT